39results about How to "Inhibition of chemotaxis" patented technology

The invention relates to an ophthalmic controlled release system of long-action low molecular heparin which comprises the low molecular heparin as drug and a drug carrier made from synthesized or natural biodegradable high molecular materials and is characterized in that the proportion range of the low molecular heparin and the drug carrier is (1:8) to (5:1); the average molecular mass of the lowmolecular heparin is less than 8000 Dalton; the molecules less than 8000 Dalton, the salt compounds of the low molecular heparin such as sodium salt, calcium salt and kali salt included, take up not less than 60 percent of the total molecules of the low molecular heparin; the synthesized or natural biodegradable high molecular materials are polyglycolic acid and gelatin or bletilia striata gelatinrespectively. The ophthalmic controlled release system of long-action low molecular heparin can effectively inhibit the proliferation and migration of lenticular epithelia and fibroblasts in eyes, reduce fibrinous exudates post operation, alleviate inflammatory reaction post operation and prevent posterior capsular opacification, thereby inhibiting the occurrence of after-cataract; meanwhile, theophthalmic controlled release system of long-action low molecular heparin inhibits the proliferation of retinal pigment epithelium and fibroblasts, thus inhibiting the proliferative vitreoretinopathy(PVR).

The invention provides an oral Andrias davidianus liquid for eyesight improvement. The oral liquid is prepared through using the following raw materials, by weight, 6-10 parts of an Andrias davidianus eye, 8-12 parts of an Andrias davidianus liver, 40-60 parts of Andrias davidianus skin, 8-12 parts of Lycium Chinense, 8-12 parts of wild chrysanthemum flower, 8-12 parts of white peony root, 18-22 parts of unprepared rehmannia root, 8-12 parts of honey, and 8-12 parts of morchella. A preparation method of the oral liquid comprises the following steps: adding water having a weight 2-3 times the raw materials except honey to the raw materials except honey, decocting with a slow fire for 1.5-2h, filtering, adding honey, uniformly mixing, cooling, and canning to obtain the oral Andrias davidianus liquid for eyesight improvement. The oral Andrias davidianus liquid has the efficacies of liver cleaning, eyesight improving, kidney yin nourishing and the like, and can improve the organism immunity, promote the brain development, prevent senile dementia, protect the eyesight and delay ageing through frequent drinking.

The invention provides an oral giant salamander liquid for brain strengthening. The oral liquid is prepared through using the following raw materials, by weight, 150-250 parts of a giant salamander brain, 10-20 parts of a giant salamander liver, 4-8 parts of ginseng, 15-25 parts of Lycium Chinense, 25-35 parts of lotus seed, 8-12 parts of brown sugar, 8-12 parts of walnut kernel, 15-25 parts of Dioscorea opposita and 15-25 parts of red date. A preparation method of the oral liquid comprises the following steps: adding water having a weight 2-3 times raw materials except brown sugar to the raw materials except brown sugar, decocting with a slow fire for 1.5-2h, filtering, adding brown sugar, uniformly mixing, filtering, cooling, and canning. The oral liquid has the efficacies of essence replenishing, blood tonifying, brain strengthening, intelligence developing, liver and kidney nourishing, heart fire clearing, vexation eliminating, qi tonifying, blood nourishing and the like, and can be adapted to all age groups.

The invention discloses anti-inflammatory application of a small molecule compound AG-4, and application in preparing anti-inflammatory drug. The small molecule compound AG-4 is screened through a candidate drug screening platform combining structural biology, information biology and biological activity determination. The small molecule compound AG-4 can realize specific binding with CD147 protein to inhibit inflammatory cell chemotaxis and secretion of chemotaxis; the invention is also suitable for preparing medicines for treating CD147 protein high expression related diseases (such as rheumatoid arthritis).

The invention relates to VHH (variable domain of heavy chain of heavy-chain antibody) antibody gene derived from anti-CyPA (CyclophilinA) animal of family Camelidae, encoded polypeptide, and application of the gene and the polypeptide in preparing drugs for treating inflammatory diseases such as rheumatoid arthritis. The VHH antibody gene has gene sequence shown in sequence table (400)1, the encoded polypeptide has amino acid sequence shown in sequence table (400)2. Lama pacos as immune animal is used, and phage display techniques (PDT) are adopted to successfully obtain an anti-CyPA VHH antibody capable of specifically combining with expressed CyPA antigen. The antibody can inhibit monocytes THP-1 chemotaxis and gelatinase secretion induced by CyPA. Dimer or polymer can be constructed by gene engineering method, to be applied in diagnosis or research on drugs for treating inflammatory diseases. The gene and the polypeptide establish foundation for further research on related drugs for treating rheumatoid arthritis.

The invention discloses 1-(5-(3-((4-chlorobenzyl)amino)-2-hydroxypropoxy)-2-methyl-1-(p-tolyl)-1hydro-indole- 3-yl) ethyl ketone for the treatment or prevention of inflammatory diseases, for the prevention and / or alleviation and / or auxiliary treatment and / or treatment of inflammatory diseases, such as bronchitis, pneumonia, hepatitis, rhinitis, enteritis, gastritis , nephritis, dermatitis, prostatitis, vaginitis, rheumatism, etc. The present invention 1-(5-(3-((4-chlorobenzyl) amino)-2-hydroxypropoxy)-2-methyl-1-(p-tolyl)-1 hydrogen-indole-3- Base) ethyl ketone has specific inhibitory effect on PI3Kγ, and has inhibitory effect on inflammatory cell proliferation and chemotaxis. The compound of the present invention can inhibit inflammatory response by inhibiting PI3Kγ.

The present invention provides a recombinant protein or a derivative thereof, wherein the recombinant protein has an amino acid sequence of the N-terminal portion of CC chemokine receptor 4 (CCR4). The invention also provides the use of the recombinant protein or a derivative thereof for treating or preventing a disease or condition associated with CCR4 signaling, such as an allergic disease, inflammatory enteritis, psoriasis, an inflammatory skin disease, vasculitis, spondyloarthropathy, scleroderma, asthma, a respiratory allergic disease, an autoimmune disease, graft rejection, leukemia, lymphoma, a blood-borne cancer, a disease requiring inhibition of undesirable inflammation, and a cancer.